search
  • Country
    Clear
  • Type
  • Compatibility Level
  • Thematic
  • Jurisdiction
3,269 Data sources

  • NL
  • ES
  • SG
  • DZ

  • more_vert
  • This site provides access to the research outputs of the institution. Users may set up RSS feeds. The interface is in Spanish.

    more_vert
  • more_vert
  • more_vert
  • This repository provides open access to the work of staff and students of Universidad Europea. the interface is in Spanish and English.

    more_vert
  • more_vert
  • more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • This site provides access to the audio and video output of the institution. The interface is in a mixture of Spanish and English. Users may set up RSS feeds to be alerted to new content. Some items are not available as full-text.

    more_vert
  • more_vert
  • chevron_left
  • 4
  • 5
  • 6
  • 7
  • 8
  • chevron_right
3,269 Data sources
  • more_vert
  • This site provides access to the research outputs of the institution. Users may set up RSS feeds. The interface is in Spanish.

    more_vert
  • more_vert
  • more_vert
  • This repository provides open access to the work of staff and students of Universidad Europea. the interface is in Spanish and English.

    more_vert
  • more_vert
  • more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • This site provides access to the audio and video output of the institution. The interface is in a mixture of Spanish and English. Users may set up RSS feeds to be alerted to new content. Some items are not available as full-text.

    more_vert
  • more_vert
  • chevron_left
  • 4
  • 5
  • 6
  • 7
  • 8
  • chevron_right